Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

240.48 +0.55 (+0.23%)

Streaming Delayed Price Updated: 12:23 PM EDT, Mar 26, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,746,979
Open	240.00
Bid (Size)	240.39 (100)
Ask (Size)	240.51 (100)
Prev. Close	239.93
Today's Range	238.93 - 240.83
52wk Range	141.50 - 251.71
Shares Outstanding	2,628,679,824
Dividend Yield	2.16%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics

Today 10:09 EDT

Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more...

Via Finterra

The Fear Gauge Ascendant: VIX Hits 26 as Geopolitical Storms and 'Higher-for-Longer' Reality Grip Markets

March 24, 2026

The CBOE Volatility Index (VIX), Wall Street’s premier measure of expected stock market volatility, climbed to a reading of 26.15 this week, marking its highest sustained level in nearly two years. As...

Via MarketMinute

Performance

YTD	+16.0%	+16.0%
1 Month	-2.2%	-2.2%
3 Month	+15.7%	+15.7%
6 Month	+36.1%	+36.1%
1 Year	+49.3%	+49.3%

More News

If You Only Own Tech Stocks, Jim Cramer Has a Blunt Warning for You in 2026 ↗

March 23, 2026

Via The Motley Fool

Johnson & Johnson (JNJ) Forecast: Extended Rally Signals Patience for Buyers ↗

March 17, 2026

Via Talk Markets

FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market

March 23, 2026

Via MarketMinute

1 Dividend ETF That Could Turn $500 Monthly Into a $725,000 Portfolio That Pays $21,750 Annually ↗

March 20, 2026

Via The Motley Fool

Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie ↗

March 19, 2026

Via Benzinga

2 Reasons to Buy Johnson & Johnson Stock Like There's No Tomorrow ↗

March 19, 2026

Via The Motley Fool

AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown

March 18, 2026

Via MarketMinute

The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms

March 18, 2026

Via MarketMinute

2 Stocks That Could Create Lasting Generational Wealth ↗

March 17, 2026

Via The Motley Fool

The $40 Billion Pivot: Kimberly-Clark and Kenvue Merger Redefines the Consumer Staples Landscape

March 16, 2026

Via MarketMinute

Your Tax Refund Will Probably Be Bigger This Year. Here's What to Do With It. ↗

March 16, 2026

Via The Motley Fool

Stryker Corporation (SYK): Navigating Innovation and Resilience in the Wake of a Digital Crisis

March 16, 2026

Via Finterra

Johnson & Johnson’s Trial In Early-Stage Bladder Cancer Yield Positive Safety Results ↗

March 13, 2026

Via Stocktwits

Flight to Quality: JPMorgan and Eli Lilly Emerge as Defensive Anchors Amid Geopolitical Storm

March 13, 2026

Via MarketMinute

The Best Dividend Stocks to Buy and Hold Forever ↗

March 12, 2026

Via The Motley Fool

1 No-Brainer S&P 500 Vanguard ETF to Buy Right Now for Less Than $1,000 ↗

March 12, 2026

Via The Motley Fool

The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)

March 12, 2026

Via Finterra

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

March 12, 2026

From Johnson & Johnson

Via Business Wire

End of an Era: West Pharmaceutical Shares Slide as Longtime CEO Eric Green Announces Retirement

March 11, 2026

Via MarketMinute

Cracks in the Bull Case: S&P 500 Breaches Key Support as Institutional Distribution Takes Hold

March 11, 2026

Via MarketMinute

Safe Haven in a Storm: Healthcare Leads Markets as Geopolitical Tensions Spark Defensive Rotation

March 10, 2026

Via MarketMinute

Quiet Outperformance From an Overlooked Dividend ETF ↗

March 09, 2026

Via MarketBeat

2 No-Brainer Dividend Stocks to Buy in 2026 ↗

March 08, 2026

Via The Motley Fool

Frequently Asked Questions

Is Johnson & Johnson publicly traded?

Yes, Johnson & Johnson is publicly traded.

What exchange does Johnson & Johnson trade on?

Johnson & Johnson trades on the New York Stock Exchange

What is the ticker symbol for Johnson & Johnson?

The ticker symbol for Johnson & Johnson is JNJ on the New York Stock Exchange

What is the current price of Johnson & Johnson?

The current price of Johnson & Johnson is 240.48

When was Johnson & Johnson last traded?

The last trade of Johnson & Johnson was at 03/26/26 12:23 PM ET

What is the market capitalization of Johnson & Johnson?

The market capitalization of Johnson & Johnson is 632.14B

How many shares of Johnson & Johnson are outstanding?

Johnson & Johnson has 632B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.